TY - JOUR
T1 - Comparative pharmacological analysis of Rho-kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract
AU - Teixeira, Cleber E.
AU - Jin, Liming
AU - Priviero, Fernanda B.M.
AU - Ying, Zhekang
AU - Webb, R. Clinton
N1 - Funding Information:
This study was supported by grants from the National Institutes of Health (HL-71138, HL-74167).
PY - 2007/8/15
Y1 - 2007/8/15
N2 - We aimed to compare the expression and function of molecular components of the RhoA/Rho-kinase signaling pathway in the contractile responses of detrusor, trigonal and urethral smooth muscle, using selective Rho-kinase inhibitors. Contractility studies and molecular approaches were employed to demonstrate the expression patterns and functional activity of the RhoA/Rho-kinase signaling pathway in the lower urinary tract. Frequency-response curves (1-32 Hz) and concentration-response curves (CRC) to carbachol (CCh, 0.01-30 μM), phenylephrine (PE, 0.01-300 μM) and endothelin-1 (ET-1, 0.01-100 nM) were significantly attenuated (p < 0.01) following incubation with the Rho-kinase inhibitors H-1152 (0.1-1 μM), Y-27632 (1-10 μM) or HA-1077 (10 μM). Addition of Rho-kinase inhibitors also markedly reduced (p < 0.01) the contractions evoked by either KCl (80 mM) or α,β-methylene ATP (α,β-mATP, 10 μM). Among the Rho-kinase inhibitors tested, H-1152 was approximately 9-16 times more potent than Y-27632 or HA-1077. In addition, basal tone of detrusor and trigonal strips was reduced following addition of Y-27632 (10 μM), H-1152 (1 μM) and HA-1077 (10 μM). The expression of RhoA, RhoGDI, leukemia-associated RhoGEF (LARG) and p115RhoGEF was similar among the detrusor, trigone and urethra, whereas Rho-kinase α, Rho-kinase β and PDZ-RhoGEF protein levels were significantly lower in the urethra. Components of the RhoA/Rho-kinase signaling are expressed in detrusor, trigonal and urethral smooth muscle and dynamically regulate contraction and tone. Manipulation of RhoGEF expression may provide further understanding of mechanisms involving Ca2+ sensitization in the lower urinary tract.
AB - We aimed to compare the expression and function of molecular components of the RhoA/Rho-kinase signaling pathway in the contractile responses of detrusor, trigonal and urethral smooth muscle, using selective Rho-kinase inhibitors. Contractility studies and molecular approaches were employed to demonstrate the expression patterns and functional activity of the RhoA/Rho-kinase signaling pathway in the lower urinary tract. Frequency-response curves (1-32 Hz) and concentration-response curves (CRC) to carbachol (CCh, 0.01-30 μM), phenylephrine (PE, 0.01-300 μM) and endothelin-1 (ET-1, 0.01-100 nM) were significantly attenuated (p < 0.01) following incubation with the Rho-kinase inhibitors H-1152 (0.1-1 μM), Y-27632 (1-10 μM) or HA-1077 (10 μM). Addition of Rho-kinase inhibitors also markedly reduced (p < 0.01) the contractions evoked by either KCl (80 mM) or α,β-methylene ATP (α,β-mATP, 10 μM). Among the Rho-kinase inhibitors tested, H-1152 was approximately 9-16 times more potent than Y-27632 or HA-1077. In addition, basal tone of detrusor and trigonal strips was reduced following addition of Y-27632 (10 μM), H-1152 (1 μM) and HA-1077 (10 μM). The expression of RhoA, RhoGDI, leukemia-associated RhoGEF (LARG) and p115RhoGEF was similar among the detrusor, trigone and urethra, whereas Rho-kinase α, Rho-kinase β and PDZ-RhoGEF protein levels were significantly lower in the urethra. Components of the RhoA/Rho-kinase signaling are expressed in detrusor, trigonal and urethral smooth muscle and dynamically regulate contraction and tone. Manipulation of RhoGEF expression may provide further understanding of mechanisms involving Ca2+ sensitization in the lower urinary tract.
KW - Detrusor
KW - Rho-kinase
KW - RhoA
KW - RhoGEFs
KW - Trigone
KW - Urethra
UR - http://www.scopus.com/inward/record.url?scp=34447284478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447284478&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2007.06.004
DO - 10.1016/j.bcp.2007.06.004
M3 - Article
C2 - 17603024
AN - SCOPUS:34447284478
SN - 0006-2952
VL - 74
SP - 647
EP - 658
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 4
ER -